Bright Minds Bioscience: A Deep Dive

Today we are diving into a firm focused on mental health, whom is also a recently Nasdaq-listed Psychedelic Stock, Bright Minds Biosciences (NASDAQ: DRUG). The firm is focused on the development of second generation psychedelic pharmaceuticals for treatment of neuropsychiatric disorders, which will maintain IP protections, unlike its peers whom are largely focused on first generation psychedelic compounds.

As of the last quarter, the company had $22M cash on the balance sheet with only 12M shares outstanding. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs, with members of its scientific team including renowned scientists like Dr. Alan Kozikowski and Dr. Gideon Shapiro.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Bright Minds Bioscience Approved For Nasdaq Listing

There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience (CSE:...

Wednesday, November 3, 2021, 08:50:22 AM

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after...

Monday, September 20, 2021, 10:09:00 AM

Bright Minds: The Next Revolution In Mental Health Care – The Daily Dive

Today on the Daily Dive, our host Cassandra Leah sits down with Ian McDonald, CEO...

Tuesday, May 4, 2021, 01:30:00 PM

Bright Minds Biosciences Proprietary Compound Shows Reduction Of Seizures In Pre-Clinical Studies

Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being...

Wednesday, August 18, 2021, 08:54:44 AM

Bright Minds: Focusing On Second Generation Psychedelic Compounds – The Daily Dive

Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom...

Monday, June 21, 2021, 01:30:00 PM